A new report from GlobalData UK indicates that the market for HER2-positive breast cancer treatments could grow from $6.4 billion in 2015 to $9.89 billion in 2025, a compound annual growth rate (CAGR) of 4.4%.
A new report from GlobalData UK indicates that the market for HER2-positive breast cancer treatments could grow from $6.4 billion in 2015 to $9.89 billion in 2025, a compound annual growth rate (CAGR) of 4.4%.
The report, which examines the HER2-positive treatment market in the United States, the United Kingdom, France, Germany, Italy, Spain, Japan, and China, indicates that the adjuvant and neoadjuvant settings of the market, which the report’s authors say will reach $4.96 billion by 2025, are likely to emerge as the main drivers of sales. The biggest sales driver is expected to be the monoclonal antibody pertuzumab (Roche’s Perjeta) used in first-line therapy for HER2-positive metastatic breast cancer in combination with trastuzumab (Herceptin) and docetaxel.
Because pertuzumab and the reference trastuzumab are believed to work in complementary ways to increase death of cancer cells, increased use of pertuzumab could help protect sales of Herceptin in a landscape with growing numbers of biosimilar options, the authors say. Perjeta will also extend the duration of treatment, contributing to higher sales numbers.
Max Bourgognon, healthcare analyst for GlobalData, explained the staying power of the monoclonal antibodies in the marketplace, saying, “The dynamism of the adjuvant and neoadjuvant markets has prompted many companies to position their products in these settings. However, many agents have failed to demonstrate clinical benefit over the currently cemented standard of care, meaning the adjuvant and neoadjuvant settings will remain an exclusive market for anti-HER2 monoclonal antibodies, hence constituting the most lucrative opportunity for biosimilar developments.”
The report also indicates that the anticipated launch of Puma Biotechnology's neratinib in late 2017 could create a new treatment setting for the treatment of HER2-positive breast cancer: the extended adjuvant setting, a currently underexplored area that could boom as additional drug manufacturers seek market share. Neratinib, a tyrosine kinase inhibitor (TKI), blocks signal transduction through the epidermal growth factor receptors HER1, HER2, an HER4. Puma Biotechnology says that it sees the potential for the oral treatment to be used in several additional indications, including gastric cancer. The drug was recommended for approval by the FDA's Oncologic Drugs Advisory Committee (ODAC) in May.
As promising as new TKIs may be, the report notes that there remains room for new products, and that patients who have TKI-resistant HER2-positive cancer remain an especially underserved segment of the patient population that will require innovative therapies to meet their needs.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.